Phase Ib/II Study of Selinexor in Combination with Carfilzomib, subcutaneous Isatuximab administered via investigational device, and Dexamethasone (SCID) for Patients with Relapsed and/or Relapsed Refractory Multiple Myeloma
Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma
